Skip to content
Medical Health Aged Care

Trial shows saliva is on par with blood tests for managing epilepsy through keto diet

Monash University 2 mins read

A simple saliva test could transform the lives of millions of children and adults worldwide who are on the keto diet to manage their epilepsy, and who currently endure uncomfortable finger prick tests.  

 

Monash researchers, in collaboration with China’s Shenzhen Children’s Hospital and the global biotech firm MX3 Diagnostics, found that MX3’s handheld test was comparable in accuracy to existing blood tests. Urine and breath testing are also less invasive, but much less accurate. 

 

The device, called the MX3 LAB, utilises a test strip to non-invasively measure salivary levels of ketones - acids that are released when the body burns fat instead of carbohydrates for energy. 

 

People living with epilepsy and other conditions – especially children with drug-resistant epilepsy – are often prescribed the ketogenic diet, which has been proven to reduce seizures. Knowing their ketone levels allows them to adjust the composition and timing of their food intake to help further reduce symptoms. 

 

Joint first author Dr Neha Kaul, a neuroscience researcher at Monash University’s School of Translational Medicine, said the test would be a game changer for parents, especially of younger children. 

 

“All that’s needed is for the tongue to touch the test strip for just a few seconds, and you can see the results in 30 seconds, without having to endure a painful finger prick test,” Dr Kaul said. “Being able to manage not only your kids’ diet but also eliminate some of the discomfort of living with the condition is going to really help.” 

 

“Parents could administer the test in the morning and use the information for their menu planning the same day.”

 

The study was published in the journal Epilepsia. Blood and saliva samples from some 40 children (with a median age of four and a half years) were taken on day one and day seven of a week-long admission to the SCH to start ketogenic diet therapy for the first time. The researchers found that the results correlated with ketone levels in the blood. 

 

MX3 CEO Michael Luther said, “Nobody likes to give blood. Even a finger prick can be painful, especially when done every day. The breakthrough biomarker testing system that the MX3 team has developed will significantly improve quality of life for these brave kids who are really just interested in leading a normal, pain-free life.” 

 

Further research is needed to determine whether the test has similar accuracy in infants, and its accuracy for people who have been on the ketogenic diet for a prolonged period. 

 

The project was undertaken as part of a larger collaborative program, the Shenzhen Sanming Project, with Professor Ingrid Scheffer from The University of Melbourne, and other researchers.

 

The clinical benefits of the test are now being validated in a telehealth clinical trial conducted by Monash University through Alfred Health, via a Medical Research Future Fund (MRFF) grant, which will conclude in 2027

- ENDS -

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site 

 

About MX3

MX3 Diagnostics is a digital health company based in Austin, TX and Melbourne, Australia. MX3 has developed an advanced biomarker testing system that uses saliva and sweat to provide real-time personalized diagnostics and health insights. Our clinically validated testing solutions and cloud analytics are deployed by over 600 elite sports teams, Fortune 1000 companies, government agencies, and healthcare facilities around the world.

More from this category

  • Medical Health Aged Care
  • 10/07/2025
  • 21:40
Sinovac Biotech Ltd.

Newly Elected Directors of Sinovac Hold the First Board Meeting

Mr. Andrew Y. Yan elected Chairman of the BoardNew Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin…

  • General News, Medical Health Aged Care
  • 10/07/2025
  • 19:00
Breast Cancer Network Australia

Count Us In. From Australia to the World: Global Leaders Unite to End the Invisibility of Metastatic Breast Cancer

MEDIA RELEASE Count Us In. From Australia to the World: Global Leaders Unite to End the Invisibility of Metastatic Breast Cancer BCNA in London, United Kingdom – 10 July 2025 Today, three of the world's leading breast cancer organisations have united in a groundbreaking global call to action that could transform cancer care worldwide—demanding that people living with metastatic breast cancer are finally counted, recognised, and supported. Breast Cancer Network Australia (BCNA), Breast Cancer Now (UK), and Rethink Breast Cancer (Canada) launched the historic 'Advancing Global Visibility for Metastatic Breast Cancer' Advocacy Pledge at the Australian High Commission in London,…

  • Contains:
  • Environment, Medical Health Aged Care
  • 10/07/2025
  • 10:43
Doctors for the Environment Australia

MEDIA RELEASE: Federal Court Hearing: Doctors for the Environment Australia v NOPSEMA and Woodside

10 July 2025 Federal Court Hearing – July 14-15 What: Two days of legal argument regarding validity of The National Offshore Petroleum Safety and Environmental Management Authority’s (NOPSEMA) acceptance of the Environmental Plan for Woodside’s Scarborough Gas Project When: From 10:15am, Monday and Tuesday, July 14 and 15 Where: Court No. (TBA), Federal Court of Australia, 305 William St, Melbourne Who: Applicant — Doctors for the Environment Australia (DEA) Respondents — NOPSEMA and Woodside Energy Presiding Judge — Hon Justice Shaun McElwaine Case name: Doctors for the Environment (Australia) Incorporated v National Offshore Petroleum Safety and Environmental Management Authority &…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.